Daily Ards Research Analysis
Analyzed 5 papers and selected 3 impactful papers.
Summary
Today's selection spans prospective cohort, mechanistic, and large registry research. A multicountry cohort shows uncomplicated malaria co-infection does not worsen ambulatory COVID-19 outcomes and prior malaria exposure may hasten recovery; a mechanistic NRDS study identifies a miR-574-5p/RAB10 axis regulating inflammation; and a national trauma registry details contemporary ECMO utilization, timing, and outcomes.
Research Themes
- Coinfection and host immunity effects on viral illness trajectory
- MicroRNA-mediated inflammatory regulation in neonatal lung disease
- Epidemiology and outcomes of ECMO in trauma care
Selected Articles
1. Uncomplicated malaria as a risk factor for COVID-19 duration and severity in western Kenya and Burkina Faso (MALCOV): a prospective cohort study.
In a prospective cohort of 742 ambulatory COVID-19 patients in Kenya and Burkina Faso, 20% had uncomplicated malaria co-infection. Symptom resolution times were similar between co-infected and non-co-infected patients (median 9 vs 10 days; aHR 1.14; p=0.26), with comparable hospitalization and mortality. Prior malaria exposure significantly modified outcomes, accelerating symptom clearance.
Impact: This multicountry, prospective study provides high-quality evidence that treated, uncomplicated malaria co-infection does not worsen ambulatory COVID-19 outcomes, clarifying a debated area and highlighting potential protective effects of prior malaria exposure.
Clinical Implications: In ambulatory settings, routine alteration of COVID-19 management solely due to uncomplicated malaria co-infection may be unnecessary if malaria is promptly treated; assessment of prior malaria exposure may aid risk stratification.
Key Findings
- Among 742 COVID-19 patients, 151 (20%) had uncomplicated malaria co-infection; co-infected patients were younger (32% <15 years vs 6%; p<0.0001).
- Time to symptom resolution was similar between groups (median 9 vs 10 days; adjusted HR 1.14, 95% CI 0.91–1.42; p=0.26).
- Hospitalizations (2% vs 2%) and deaths (1% vs 1%) were comparable; four deaths were due to acute respiratory distress syndrome.
- Previous malaria exposure significantly modified outcomes, with exposed co-infected individuals clearing symptoms faster.
Methodological Strengths
- Prospective, multicountry cohort with daily symptom tracking using a validated patient-reported outcome (FLU-PRO Plus).
- Serial RT-qPCR viral load measurements through day 28 and adjusted analyses for key covariates.
Limitations
- Observational design with potential residual confounding and age distribution differences between groups.
- Findings pertain to ambulatory, appropriately treated cases and may not generalize to hospitalized severe disease.
Future Directions: Investigate immunological mechanisms underlying the modifying effect of prior malaria exposure on viral illness and assess generalizability to severe COVID-19 and other respiratory viruses.
BACKGROUND: The relationship between malaria and COVID-19 varies across different clinical scenarios; historical malaria exposure might protect against severe COVID-19, whereas co-infection in hospitalised patients with severe disease might increase mortality. Interactions between non-severe malaria and COVID-19 remain poorly understood. We conducted a cohort study among COVID-19 patients of all ages in western Kenya and Burkina Faso to assess the effects of acute, uncomplicated Plasmodium falciparum malaria co-infection on COVID-19 outcomes in ambulatory patients. METHODS: Participants with laboratory-confirmed SARS-CoV-2 infection (positive rapid antigen test or reverse transcription quantitative real-time PCR [RT-qPCR]) were tested for malaria by rapid antigen tests with confirmatory microscopy. Patients with COVID-19 and malaria co-infection received artemether-lumefantrine or pyronaridine-artesunate. COVID-19 symptom course was assessed daily using FLU-PRO Plus (a validated patient-reported outcome instrument) until day 14. Viral load was measured by RT-qPCR on days 0, 3, 7, 14, and 28. The primary endpoint was time to symptom resolution on the FLU-PRO Plus. Analyses were adjusted for country, age, disease severity, and viral load. FINDINGS: Between Jan 8, 2021 and Jan 24, 2022, we screened 5161 participants and recruited 756 with COVID-19. 742 participants with valid malaria tests were enrolled, of which 151 (20%) had malaria co-infection and the remaining 591 (80%) did not have malaria. Patients with malaria were younger (49 [32%] aged <15 years) than those without malaria (35 [6%]; p<0·0001). Time to symptom resolution was similar between those with malaria (median 9 days [IQR 5-13]) and those without (10 days [IQR 6-13]; adjusted hazard ratio [aHR] 1·14 [95% CI 0·91-1·42]; p=0·26). Three (2%) patients with malaria and nine (2%) without malaria were hospitalised; two (1%) with malaria and three (1%) without malaria died, four from acute respiratory distress syndrome and one (in the no malaria group) from perforated peptic ulcer complicated by anaemia. Participants with malaria more frequently reported moderate-to-severe symptoms at enrolment (68% vs 60%; p=0·074), but overall symptom duration was similar (adjusted incidence rate ratio 0·95 [95% CI 0·86-1·05]; p=0·31). Previous malaria exposure significantly modified outcomes, with patients with malaria co-infection and previous exposure having faster symptom clearance than those without previous exposure (p INTERPRETATION: This study shows that acute uncomplicated malaria co-infection does not adversely affect COVID-19 progression when appropriately treated. Moreover, serological evidence confirms that previous lifelong malaria exposure might provide some protection, with exposed individuals having faster symptom resolution. FUNDING: Gates Foundation. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
2. The downregulation of RAB10 by miR-574-5p alleviates the inflammatory response in neonatal respiratory distress syndrome.
Serum and cell data show miR-574-5p is downregulated and RAB10 upregulated in NRDS, with miR-574-5p overexpression reducing LPS-induced inflammatory cytokine secretion in alveolar epithelial cells. Overexpressing RAB10 negated miR-574-5p’s anti-inflammatory effects, implicating a miR-574-5p/RAB10 axis in NRDS inflammation and suggesting diagnostic and therapeutic potential.
Impact: By mechanistically linking a specific microRNA to RAB10-mediated inflammatory signaling in NRDS across clinical samples and in vitro models, this work identifies a plausible biomarker and therapeutic target in a disease lacking targeted therapies.
Clinical Implications: miR-574-5p measurement could aid early NRDS diagnosis and risk stratification, while therapeutic modulation of the miR-574-5p/RAB10 axis may attenuate pulmonary inflammation pending validation.
Key Findings
- miR-574-5p was decreased and RAB10 increased in NRDS neonates and in LPS-stimulated HPAEpiCs.
- miR-574-5p mimic reduced, while miR-574-5p inhibitor increased, LPS-induced inflammatory cytokine secretion in alveolar epithelial cells.
- RAB10 overexpression reversed the anti-inflammatory effect of miR-574-5p, supporting a functional miR-574-5p/RAB10 regulatory axis.
Methodological Strengths
- Combined human case-control serum analysis with mechanistic in vitro assays.
- Dual-luciferase reporter assays confirming miRNA–target (RAB10) interaction, plus ELISA and RT-qPCR quantification.
Limitations
- Case-control and in vitro design limits causal inference and clinical generalizability; single-cell-line model.
- Lack of external validation and prospective clinical outcomes linking biomarker modulation to patient benefit.
Future Directions: Validate serum miR-574-5p/RAB10 as diagnostic/prognostic biomarkers in multicenter neonatal cohorts and test therapeutic modulation in relevant preclinical models.
AIM: The diagnosis of neonatal respiratory distress syndrome NRDS relies on progressive breathing difficulties after birth, abnormal blood oxygen levels, and typical chest X-ray images. However, this diagnostic method has insufficient specificity and is difficult to make a differential diagnosis. Pulmonary surfactant replacement and respiratory support are the main treatment methods for NRDS, but targeted therapy is still lacking. Serum miRNA detection has high sensitivity and specificity. This study explored the miR-574-5p/RAB10 axis, providing potential molecular targets for the early diagnosis and treatment development of NRDS. MATERIALS AND METHODS: This study included 110 non-NRDS and 110 NRDS newborns. The NRDS-related alveolar epithelial injury model was established by stimulating HPAEpiCs with LPS to verify the regulatory effect of the miR-574-5p/RAB10 signaling axis on the secretion of inflammatory factors. The level of miR-574-5p and RAB10 in serum and HPAEpiCs was detected by RT-qPCR. The secretion of inflammatory factors was tested by ELISA. The dual luciferase reporter gene assay was employed to investigate the targeting relationship between miR-574-5p and RAB10. The correlation between clinical factors and miR-574-5p expression was analyzed in NRDS by the chi-square test. RESULTS: The miR-574-5p expression was reduced in NRDS newborns and HPAEpiCs stimulated by LPS, while the RAB10 expression increased. The ELISA indicated that the secretion of inflammatory factors was increased in HPAEpiCs cells stimulated by LPS. The secretion levels of inflammatory factors were decreased after transfection with miR-574-5p mimic, while transfection with the miR-574-5p inhibitor, the secretion levels were increased. Overexpression of RAB10 overturned the anti-inflammatory role of miR-574-5p mimic. CONCLUSIONS: This study demonstrated that the miR-574-5p/RAB10 signaling axis plays a crucial role in regulating the inflammation in NRDS. This not only provides potential molecular markers for the early diagnosis of NRDS but also identifies miR-574-5p as a potential therapeutic target for NRDS.
3. An epidemiological analysis of extracorporeal membrane oxygenation use in trauma.
In a national trauma registry (2017–2023), ECMO was used in 1,919 of 8,014,737 encounters, with median initiation 44 hours after arrival and annual survival 59–68%. Utilization spanned 103–158 facilities annually and increased over time; interfacility transfer was common but not associated with survival.
Impact: Provides contemporary, large-scale benchmarks for ECMO timing, incidence, and outcomes in trauma, informing system-level planning and potential guideline development.
Clinical Implications: Benchmarks support referral pathways, resource allocation, and timing considerations for ECMO in trauma; similar survival across transfers suggests centralization strategies should weigh logistics without expecting survival penalties.
Key Findings
- ECMO was documented in 1,919 of 8,014,737 trauma encounters (incidence 1.9–2.9 per 10,000 annually).
- Median time from hospital arrival to ECMO initiation was 44 hours (IQR 5–147).
- Annual survival ranged from 59% to 68% over the study period.
- Number of facilities performing ECMO increased from 103 to 158 annually; interfacility transfer was common and not associated with survival.
Methodological Strengths
- Very large, national registry with multi-year coverage and both adult and pediatric analyses.
- Clear procedural identification of ECMO and reporting of timing and facility-level metrics.
Limitations
- Retrospective registry with potential coding misclassification and limited clinical granularity.
- Confounding and selection bias cannot be fully addressed; lack of patient-level indications and severity metrics.
Future Directions: Linkage with detailed clinical severity indices and prospective registries to refine patient selection criteria and optimal timing for trauma ECMO.
BACKGROUND: Trauma is the leading cause of death in younger adults and children. Severe polytrauma predisposes patients to the failure of multiple organ systems, including the cardiovascular and respiratory systems, at times necessitating extracorporeal membrane oxygenation (ECMO). ECMO use in the setting of trauma is increasing, yet little data exists describing current practice patterns. We performed an epidemiological analysis of ECMO use and outcomes in trauma patients. STUDY DESIGN AND METHODS: We analyzed data from the Trauma Quality Improvement Program Registry from 2017 to 2023. Procedure codes were used to identify the application of ECMO. Pediatric patients were those < 18 years of age. We analyzed two groups from this data set: one including all patients who required ECMO and a separate group including only pediatric cases. We used descriptive and inferential statistical methods. RESULTS: There were 8,014,737 encounters of which 1919 had documented ECMO use. Within that group, 224 were < 18 years of age. The median time from hospital arrival to the first initiation of ECMO was 44 h (interquartile range [IQR] 5-147). The incidence per year ranged from 1.9 to 2.9 events per 10,000 encounters. Survival ranged from 59% to 68% per year. The number of facilities with documented ECMO use annually ranged from 103 to 158 and overall increased during the time of the study. Interfacility transfer was common but was not related to survival. DISCUSSION: ECMO use demonstrated steady growth in the number of performing facilities throughout the study period. Survival was similar to previous reports. Our findings will help inform targeted clinical guidelines for the use of ECMO in adult and pediatric trauma populations.